DanCann Pharma A/S: Establishing a new benchmark in the industry as impressive test results show extreme product purity without the use of radiation

COPENHAGEN, Denmark, 16 May 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce impressive and unique results of analysis for its upcoming products.

Tetrahydrocannabinol (“THC”) is one of the active substances extracted from cannabis, and DanCann Pharma has succeeded in extracting biomaterial with a solid content of THC. Now several laboratory tests show that the products are free of contaminants and impurities without the use of radiation - a process that is common within the industry.

DanCann Pharma’s biomaterial is produced based on best practices from the pharmaceutical industry in combination with advanced environmentally controlled cultivation technology and vertical cultivation. The genetics are cultivated in boxes on several floors without the use of soil or other media, but with a specially developed system that adds the necessary fertilizers and nutrients. The automated cultivation processes and minimized external product contact have created significant results so far.

Morten Martinsen, Business Developer & Co-founder at DanCann Pharma, comments:

- We have received the analysis of the purity of our biomaterial, and we are very pleased. The results are very unique in the industry, where it has not previously been possible to achieve a similar purity without the use of radiation, and it gives us a huge boost in the continued work in our production facilities in Biotech Pharm1.

QNTM Labs is an advanced analytical laboratory providing research, development, and regulatory compliance services for pharmaceutical companies. QNTM Labs have conducted tests and chemical analysis of DanCann Pharma’s biomaterial in the company’s exclusive test environment.

Justin Ihnken, CEO of QNTM Labs, comments on the test results:

- QNTM Labs has found these results to satisfy the rigorous Danish regulatory requirements, and upon concluding analysis it was evident that the quantification levels of bacteria and microbiological organisms in DanCann Pharma’s samples were well below the allowable detection limits. We [QNTM Labs] seek to uphold the highest level of quality standards in pharmaceutical lab testing globally, and DanCann Pharma’s recent laboratory results are a testament of their approach to quality cultivation and production of medical cannabis.

By being able to avoid the irradiation step entirely, DanCann Pharma is able to conserve and preserve the valuable ingredients and active components found within the flower - and several markets have introduced a ban on the sale of irradiated products, including states in Germany.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.